Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Relatlimab in Metastatic Uveal Melanoma
NCT04552223Phase 2Completed
- Start
- Nov 2020
- Primary completion
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of relatlimab in Uveal melanoma (UM). Started Nov 2020; status: completed.
02
Drugs
relatlimab
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT04552223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04552223.